We read with interest the recent article by S. Nayak et al.
Dear Editor,
We read with interest the recent article by S. Nayak et al. [1] who concluded in a systematic review and meta-analysis study that considered the use of bisphosphonate discontinuation for bone mineral density and osteoporotic fracture risk in women who do not have low hip BMD or who have low hip BMD. This finding is important because it may provide important effectiveness of bisphosphonate in women with low hip BMD or without it so we have some concerns.
First, about the adaptation of systematic review guidelines and registrations; there have been systematic review and metaanalysis protocol registration established that help to maintain a level of homogeneity and quality across all meta-analyses and systematic reviews being conducted. PRISMA, Cochrane, JBI, and MOOSE are a few examples of such guidelines [2] [3] [4] . Therefore, the lack of any mention of the use of such instructions, even though the study itself follows the core principles of a systematic review and meta-analysis established in such statements/ guidelines, raises the question of whether any such guideline was not used or just not mentioned. Second, the authors assessed the quality of the cohort studies by Newcastle-Ottawa quality assessment scale [5] . The result about inter-rater reliability of this tool is different and ambiguous [6] . There is a disagreement between researchers that may affect the results of publications [7, 8] . Third, only four studies are clinical trials, and the limitation of evidence document may make a bias about the effectiveness of bisphosphonate in apositive or negative way, then the ethnic bias should be considered carefully. One of my concerns is that most studies conducted in the USA and studies done with similar researchers may be a barrier to generalization to population. We should consider biases in this part of article. Finally, the purpose of the systematic review is to perform interventions in society, but we should consider the cost of drug intervention especially in a developed country for implementation. We hope that the authors address the points presented and that the overall discussion of the presented points will only serve to benefit the research community at large.
